Study of SHR-1819 for prurigo nodularis
Treatments studied
Part of Skin clinical trials.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with prurigo nodularis
- You are not pregnant or breastfeeding
- You have not used a similar biologic drug (targeting IL-4Rα) before, or if you did, it did not work for you or caused side effects
- You do not have other active skin conditions or serious health problems that could affect the trial results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called MG-K10 for people with prurigo nodularis, a skin condition that causes intense itching and bumps. The goal is to see if it can help reduce itch and improve skin.
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This trial tests a new injection called SHR-1819 for people with seasonal allergies who haven't responded well to standard treatments like nasal sprays or antihistamines. It aims to see if it can reduce allergy symptoms.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Hear when a new Prurigo Nodularis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.